Abstract Details

Title Risk of Rebound in Multiple Sclerosis after a Switch from Natalizumab to Fingolimod. Early Onset versus Delayed Onset.

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 291

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Rocio Hernandez Clares, MD, PhD (Virgen De La Arrixaca Hospital) PRESENTER	No disclosure on file
Ruben Carrasco Torres	No disclosure on file
Philip Scheltens, MD, PhD, F�鶹��ýӳ�� (Alzheimer Center Amsterdam University medical Center)	Dr. Scheltens has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NOVO NOrdisk.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

�鶹��ýӳ��